Literature DB >> 17977500

Development and implementation of a medical oncology quality improvement tool for a regional community oncology network: the Fox Chase Cancer Center Partners initiative.

Margaret A O'Grady1, Elena Gitelson, Ramona F Swaby, Lori J Goldstein, Elaine Sein, Patricia Keeley, Bonnie Miller, Tianyu Li, Alan Weinstein, Steven J Cohen.   

Abstract

Fox Chase Cancer Center Partners (FCCCP) is a community hospital/academic partnership consisting of 25 hospitals in the Delaware Valley. Originally created in 1986, FCCCP promotes quality community cancer care through education, quality assurance, and access to clinical trial research. An important aspect of quality assurance is a yearly medical oncology audit that benchmarks quality indicators and guidelines and provides a roadmap for quality improvement initiatives in the community oncology clinical office setting. Each year, the FCCCP team and the Partner Medical Oncologists build disease site- and stage-specific indicators based on National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Concordance with multiple indicators is assessed on 20 charts from each community practice. A report for each FCCCP medical oncology practice summarizes documentation, screening recommendations, new drug use, and research trends in a particular disease site. Descriptive statistics reflect indicators met, number of new cases seen per year, number of disease site cases from tumor registry information, and clinical trial accrual total. Education and documentation tools are provided to physicians and oncology office nursing staff. The FCCCP Clinical Operations Team, consisting of medical oncologists and oncology-certified nurses, has conducted quality audits in medical oncology offices for 7 years using NCCN-derived indicators. Successful audits comprising gastric, colorectal, and breast cancer have been the focus of recent evaluations. For the 2005 stage II/III breast cancer evaluation, mean compliance per parameter was 88%, with 15 of 16 practices achieving mean compliance greater than 80%. A large-scale quality assurance audit in a community cancer partner network is feasible. Recent evaluation of localized breast cancer shows high compliance with guidelines and identifies areas for focused education. Partnership between academic and community oncologists produces a quality review process that is broadly applicable and adaptable to changing medical knowledge.

Entities:  

Mesh:

Year:  2007        PMID: 17977500     DOI: 10.6004/jnccn.2007.0078

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  5 in total

1.  The changing face of cancer care: evolution to a collaborative model.

Authors:  Michael Kolodziej
Journal:  Am Health Drug Benefits       Date:  2013-07

2.  Engaging Community-Based Cancer Physicians: Experience of the Memorial Sloan Kettering Cancer Center Cancer Alliance.

Authors:  Allison Lipitz-Snyderman; Jessica Kennington; Brooke Hogan; Deborah Korenstein; Leonard Kalman; Suresh Nair; Peter Yu; Paul Sabbatini; David Pfister
Journal:  J Natl Compr Canc Netw       Date:  2019-09-01       Impact factor: 11.908

3.  Assessing compliance with national comprehensive cancer network guidelines for elderly patients with stage III colon cancer: the Fox Chase Cancer Center Partners' initiative.

Authors:  Margaret A O'Grady; Elyse Slater; Elin R Sigurdson; Neal J Meropol; Alan Weinstein; Charles J Lusch; Elaine Sein; Patricia Keeley; Bonnie Miller; Paul F Engstrom; Steven J Cohen
Journal:  Clin Colorectal Cancer       Date:  2011-04-22       Impact factor: 4.481

4.  A regional quality improvement effort to increase beta blocker administration before vascular surgery.

Authors:  Philip P Goodney; Jens Eldrup-Jorgensen; Brian W Nolan; Daniel J Bertges; Donald S Likosky; Jack L Cronenwett
Journal:  J Vasc Surg       Date:  2011-02-21       Impact factor: 4.268

Review 5.  Using risk models to improve patient selection for high-risk vascular surgery.

Authors:  Philip P Goodney
Journal:  Scientifica (Cairo)       Date:  2012-12-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.